InMed Pharmaceuticals Inc. Share Price Toronto S.E.
Equities
IN
CA4576376012
Biotechnology & Medical Research
Sales 2024 * | 7.3M 5.33M 445M | Sales 2025 * | 9.12M 6.67M 556M | Capitalization | 1.91M 1.39M 116M |
---|---|---|---|---|---|
Net income 2024 * | - | Net income 2025 * | - | EV / Sales 2024 * | 0.26 x |
Net cash position 2024 * | - 0 0 | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | 0.21 x |
P/E ratio 2024 * |
-
| P/E ratio 2025 * |
-
| Employees | 13 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.64% |
Latest transcript on InMed Pharmaceuticals Inc.
Managers | Title | Age | Since |
---|---|---|---|
Eric Adams
CEO | Chief Executive Officer | 61 | 16/16/16 |
Chief Operating Officer | - | 05/18/05 | |
Colin Clancy
IRC | Investor Relations Contact | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Janet Grove
BRD | Director/Board Member | 57 | 11/22/11 |
Eric Adams
CEO | Chief Executive Officer | 61 | 16/16/16 |
Andrew Hull
CHM | Chairman | 61 | 12/16/12 |
1st Jan change | Capi. | |
---|---|---|
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.74B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |